¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-23

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-23
±³À°ÀÏÀÚ : 2022-09-23
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü  
±³À°ÁÖÁ¦ : ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)  
´ã´çÀÚ : ¿ì¿µ¼·
¿¬¶ôó : 02-3770-1139  
À̸ÞÀÏ : webmaster@thekasad.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 90,000¿ø      
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 7¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦´çÀϵî·Ï: Á¤È¸¿ø 8¸¸¿ø, ÁØȸ¿ø 6¸¸¿ø, ºñȸ¿ø 9¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø¤½      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:30~09:50 Mood and personal traits as risk factors for physical illness  È«Á¤¿Ï(Àͻ꺴¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:50~10:10 Inflammation, physical illness, and depression  ½Å»óÈ£(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:10~10:40 Metabolic syndrome and bipolar disorder  °­¿ø¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:20 Introduction to Research Domain Criteria (RDoC)  ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:20~11:45 Utility of Research Domain Criteria (RDoC) for mood disorders research  Àå½ÂÈ£(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:45~12:10 Clinical use of Research Domain Criteria (RDoC) for mood disorders  À±¼­¿µ(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:10~12:40 A paradigm shift to recover from depression  Á¤¿µÀº(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:40~13:10 Therapeutic advantage of Agomelatine in treating depression  ¼­Á¤¼®(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:30~13:50 Is bipolar patients more vulnerable to antipsychotic-induced side effects than schizophrenia patients?  ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:50~14:10 Is there a difference in therapeutic effects on somatic symptoms of depression between Selective serotonin reuptake inhibitors (SSRIs) and Serotonin and norepinephrine reuptake inhibitors (SNRIs)?  ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°­ÀÇÇаúÀÇ¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:10~14:40 What are the optimal treatment strategies for bipolar disorder in the child-bearing woman?  ¹Ú¼º¿ë(°è¿äº´¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:40 Mindfulness-based interventions for depression  ÀÌ°­¿í(°­¿øÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:50~16:10 Neurobiology of psychedelic drugs  ¹®Àº¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:10~16:30 Therapeutic potentials of psychedelic drugs  ¿ÀÈ«¼®(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:30~17:00 Evidence of psychedelic treatment for depression  °­ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ09:30~09:50 Environmental factors  ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ09:50~10:10 Genetic factors  ¾çÂù¸ð(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ10:10~10:40 Gene-environment Interaction  ÀÌ»ó¹Î(°æÈñÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ10:55~11:20 Machine learning based Electroencephalogram (EEG)  ±èÁö¼±(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ11:20~11:45 Functional Near Infrared Spectroscopy (fNIRS)  ÀÌ¿¬Á¤(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ11:45~12:10 Functional and structural Magnetic Resonance Imaging (MRI)  ÇѱԸ¸(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ12:10~12:40 Recent issue and clinical update on treatment of depressive disorders  À̹®¼ö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ12:40~13:10 Efficacy of Duloxetine on somatic symptoms and pain in depression  ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ13:30~13:50 Dialectical Behavior Therapy (DBT)  ±è¿ø(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ13:50~14:10 Pharmacotherapy  ¼ºÇü¸ð(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:10~14:40 Brain stimulation (Transcranial direct current stimulation, Transcranial Magnetic Stimulation, Electroconvulsive therapy)  ±è¼±¹Ì(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ14:40~15:10 Importance of multifactorial condition management  ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:10~15:40 Successful management of patient adherence  ½É¼¼ÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ15:50~16:10 Posttraumatic Stress Disorder (PTSD) and depression after trauma exposure  À̺´Ã¶(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:10~16:30 Suicidal behaviors associated with Posttraumatic Stress Disorder (PTSD) and depression  ÀüÁø¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-23 ¹é¹ü±è±¸±â³ä°ü ´ëȸÀǽǠ16:30~17:00 Treating depression of victims  ±è¿øÇü(ÀÎÇÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-23""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °­³²¼¼ºê¶õ½ºº´¿ø Á¦14ȸ ´ëÇѺ¹¸·¾ÏÇÐȸ Çмú ½ÉÆ÷Áö¾ö : 2022-09-24
´ÙÀ½±Û ´ëÇѼҾƳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) 2022³â Á¦3Â÷ Á¤±âÁý´ãȸ : 2022-09-23
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21062 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(4ÀÏÂ÷) : 2024-07-04 0 80 2024-06-18
21061 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀçÅÃÀÇ·á ȯÀÚ Áø·áÀÇ ½ÇÁ¦ : 2024-07-04 0 48 2024-06-18
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 69 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 12 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 77 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 54 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 42 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 39 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 66 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 51 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 45 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 63 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 28 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 25 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 20 2024-06-18
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷